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Simple Summary: Prion diseases are neurodegenerative disorders affecting humans and animals.
The development of in vitro cellular models from naturally susceptible species like humans or
ruminants can potentially make a great contribution to the study of many aspects of these diseases,
including the ability of prions to infect and replicate in cells and therapeutics. Our study shows for
the first time how ovine mesenchymal stem cells derived from bone marrow and their neural-like
progeny are able to react to scrapie prion infection in vitro and assesses the effects of this infection on
cell viability and proliferation. Finally, we observe that the differentiation of ovine mesenchymal
stem cells into neuron-like cells makes them more permissive to prion infection.
Abstract: Scrapie is a prion disease affecting sheep and goats and it is considered a prototype of
transmissible spongiform encephalopathies (TSEs). Mesenchymal stem cells (MSCs) have been
proposed as candidates for developing in vitro models of prion diseases. Murine MSCs are able to
propagate prions after previous mouse-adaptation of prion strains and, although ovine MSCs express
the cellular prion protein (PrPC), their susceptibility to prion infection has never been investigated.
Here, we analyze the potential of ovine bone marrow-derived MSCs (oBM-MSCs), in growth and
neurogenic conditions, to be infected by natural scrapie and propagate prion particles (PrPSc) in vitro,
as well as the effect of this infection on cell viability and proliferation. Cultures were kept for 48–72 h
in contact with homogenates of central nervous system (CNS) samples from scrapie or control sheep.
In growth conditions, oBM-MSCs initially maintained detectable levels of PrPSc post-inoculation, as
determined by Western blotting and ELISA. However, the PrPSc signal weakened and was lost over
time. oBM-MSCs infected with scrapie displayed lower cell doubling and higher doubling times than
those infected with control inocula. On the other hand, in neurogenic conditions, oBM-MSCs not
only maintained detectable levels of PrPSc post-inoculation, as determined by ELISA, but this PrPSc
signal also increased progressively over time. Finally, inoculation with CNS extracts seems to induce
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the proliferation of oBM-MSCs in both growth and neurogenic conditions. Our results suggest that
oBM-MSCs respond to prion infection by decreasing their proliferation capacity and thus might not
be permissive to prion replication, whereas ovine MSC-derived neuron-like cells seem to maintain
and replicate PrPSc.
Keywords: scrapie; prion; sheep; infection; mesenchymal stem cell; in vitro model
1. Introduction
Transmissible spongiform encephalopathies (TSEs) or prion diseases are fatal neu-
rodegenerative disorders that affect humans and animals [1]. These diseases are caused by
the conformational conversion of the cellular prion protein (PrPC) to an infectious isoform
that is partially resistant to proteases and prone to forming aggregates called PrPSc [2].
The accumulation of this isoform in the central nervous system (CNS) causes spongiform
neuronal degeneration, activation of glial cells and neuronal loss [3]. Scrapie, which af-
fects sheep and goats, was the first reported TSE [4] and it is considered the prototype of
these diseases [5].
Cell culture systems are useful tools to study prion protein propagation in TSEs and
to identify new prion therapeutics [6]. However, only a few cell lines can be infected and
display PrPSc accumulation and/or infectious capacity [7]. In most cases, murine cell
lines are used, requiring a previous mouse-adaptation of the prion strain to eliminate the
problem of the species barrier [8].
Mesenchymal stem cells (MSCs) are fibroblast-like cells characterized by their capacity
for both self-renewal and differentiation in mesodermal tissues (osteoblasts, adipocytes,
chondrocytes and myocytes) [9]. These cells can also transdifferentiate in vitro into neuron-
like cells [10,11] and undifferentiated cells expressing PrPC [12], which seems to play a key
role in the neuronal differentiation process of MSCs [13–15].
Murine compact bone-derived MSCs (CB-MSCs) are able to migrate to brain extracts
from prion-infected mice in vitro and significantly prolong the survival of mice infected
with the Chandler prion strain when injected in vivo [16]. Furthermore, murine bone
marrow-derived mesenchymal stem cells (BM-MSCs) can be infected with a Gerstmann–
Sträussler–Scheinker strain adapted in mice ex vivo [17] and maintain the infectivity along
passages. The susceptibility of these cells to prion infection makes them good candidates
for use in developing in vitro models for prion research [18]. Therefore, the development of
in vitro models from naturally prion-susceptible species like humans or ruminants, which
would avoid the adaptation process, would be very useful for cutting-edge prion research.
Although in recent studies, human cerebral organoids [19] and astrocytes [20], both derived
from human induced pluripotent stem cells (iPSCs), have been described to maintain and
propagate prion infectivity in vitro, in domestic species like sheep, the reprogramming of
somatic cells to iPSCs might require adjustments of standard protocols.
We have previously described the isolation of ovine MSCs from peripheral blood
(oPB-MSCs), which express PrPC at the transcript level [21]. Our group also reported the
presence of PrPC in ovine bone marrow-derived MSCs (oBM-MSCs) at both transcript
and protein levels [18]. However, in contrast to BM-MSCs obtained from individuals with
sporadic Creutzfeldt-Jakob disease (CJD), who are positive to PrPSc [12], the pathogenic
prion protein was not detected in oBM-MSCs isolated from scrapie sheep [18]. In addition
to the lack of PrPSc, these cells displayed diminished proliferation potential compared to
oBM-MSCs derived from healthy sheep. To the best of our knowledge, the susceptibility of
oBM-MSCs to scrapie infection in vitro and their potential to replicate prions have never
been investigated. The aim of the present study was to assess the susceptibility of oBM-
MSCs and their derivative neuron-like cells to scrapie prion infection in vitro, their potential
to replicate prions and the effects of this infection on cell viability and proliferation.
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2. Materials and Methods
2.1. Animals and Sample Collection
Bone marrow samples were obtained from 11 adult female (n = 7) and male
(n = 4) sheep, aged from 1 to 7 years and carrying different genotypes for the PRNP
gene (Table 1). After animal sedation (Xylazine) and local anesthesia (Lidocaine), bone
marrow aspirates were harvested from the humeral head using a 13 G Jamshidi needle and
10-mL syringes previously loaded with 0.5 mL of sodium heparin. All procedures were
carried out under Project Licence PI06/12, approved by the Ethical Committee for Animal
Experiments from the University of Zaragoza. The care and use of animals were performed
in accordance with the Spanish Policy for Animal Protection, RD53/2013, which meets
European Union Directive 2010/63 on the protection of animals used for experimental and
other scientific purposes.
Table 1. Characteristics of the animals selected to obtain bone marrow mesenchymal stem cells. The different assays in
which the ovine bone marrow-derived mesenchymal stem cells (oBM-MSCs) were used, are also shown—Western blotting
assay (WB), proliferation assay (PA), cell viability assay (MTT) and ELISA.
Sheep Genotype Sex Age (Years) Scrapie Status Breed Assay
BMO1 ARQ/ARQ Female 7 Exposed, not detected Rasa Aragonesa WB, PA
BMO2 ARQ/ARQ Female 4 Exposed, not detected Rasa Aragonesa WB, PA
BMO3 ARQ/ARQ Female 4 Exposed, not detected Rasa Aragonesa WB, PA
BMO4 ARQ/ARQ Male 1 Exposed, not detected Rasa Aragonesa MTT, ELISA
BMO5 ARQ/ARQ Male 2 Preclinical Crossbreed MTT, ELISA
BMO6 ARQ/ARQ Female 6 Exposed, not detected Ojinegra MTT, ELISA
BMO7 ARQ/ARQ Male 3 Exposed, not detected Crossbreed MTT, ELISA
BMO8 ARQ/ARQ Female 7 Exposed, not detected Rasa Aragonesa MTT
BMO9 ARR/ARQ Female 5 Exposed, not detected Rasa Aragonesa MTT
BMO10 ARQ/VRQ Female 4 Exposed, not detected Crossbreed MTT
BMO11 ARQ/VRQ Male 2 Preclinical Crossbreed MTT, ELISA
The animals used in this study were maintained in an experimental flock in which
the prevalence of scrapie was high. Although none of the animals displayed clinical signs
compatible with scrapie, an in vivo test for PrPSc determination using third-eyelid biopsies
was performed as previously described [22,23] to identify any scrapie-infected preclinical
sheep. Two males were positive to scrapie but their cultures were maintained in the study
to evaluate if these cultures could react differently to those obtained from negative sheep,
although in previous studies infectivity was not detected in oBM-MSCs derived from
scrapie sheep [18]. Negative animals were those that did not show scrapie compatible
symptoms and were negative to PrPSc based on a third-eyelid biopsy.
2.2. Ovine Mesenchymal Stem Cell Isolation and Culture
MSC isolation from bone marrow aspirates (3–5 mL) was performed following the
previously described protocol [18,21,24]. This protocol is based on the separation of
the mononuclear fraction after density gradient centrifugation in Lymphoprep (Atom)
and further isolation thanks to the ability of MSCs to adhere to plastic. After isolation,
cells were expanded up to passage 3 in basal medium, consisting of low glucose Dul-
becco’s modified Eagle’s medium (DMEM, Sigma-Aldrich, St. Louis, MO, USA) sup-
plemented with 10% fetal bovine serum (FBS), 1% L-glutamine (Sigma-Aldrich) and 1%
streptomycin/penicillin (Sigma-Aldrich).
In addition to plastic-adherence in standard culture conditions, the minimal criteria to
define MSCs are the expression of certain cell surface markers and the ability to differentiate
into adipocytes, osteoblasts and chondroblasts in vitro [25]. The ability to differentiate to
mesodermal lineages and the expression of mesenchymal and hematopoietic markers of
these cultures have been evaluated previously [18]. After characterization, the expression
of PrPC in oBM-MSCs was confirmed by RT-qPCR and dot blotting [18].
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2.3. Neurogenic Differentiation
To study whether neural differentiation increased the susceptibility to prion infection,
oBM-MSC cultures were seeded at 1500 cells/cm2 and differentiated into neuron-like cells
using HyClone neurogenic medium (Thermo Scientific, Waltham, MA, USA) according
to the manufacturer’s instructions. The differentiation process lasted three days. Neural
differentiation was monitored and confirmed by observing the cultures through an inverted
optical microscope. The formation of neuron-like cells was seen within 24 h, peaking at
72 h (Figure 1a,b), as previously described [18].
Figure 1. oBM-MSC differentiation into neuron-like cells 3 days after neurogenic induction
with HyClone neurogenic medium: (a) oBM-MSCs in growth conditions and (b) oBM-MSCs in
neurogenic differentiation.
2.4. Scrapie Inocula and Infection of oBM-MSC and Neuron-Like Cultures
Inocula were prepared using CNS samples from one healthy (negative controls) and
one classical scrapie-infected sheep carrying the ARQ/ARQ genotype and preserved at
the tissue bank of the Center of Encephalopathies and Emerging Transmissible Diseases
(CEETE; University of Zaragoza). The presence/absence of PrPSc in the tissues was con-
firmed following protocols reported in other works [26], using two rapid diagnostic tests
(Prionics-Check Western blotting; ThermoFisher Scientific and Idexx HerdChek; IDEXX,
Westbrook, ME, USA) and confirmation by immunohistochemical examination of CNS
tissue. CNS samples were homogenized and diluted 1:10 (g/mL) in physiological saline
solution (Braun). Afterwards, samples were treated at 70 ◦C for 10 min before adding
streptomycin sulphate (100 µg/mL) and benzylpenicillin (100 µg/mL). In order to check
the safety of the inocula once generated, samples were incubated in blood agar plates, and
the absence of any bacterial growth was confirmed.
To determine the effect of prion infection on the proliferation potential and the ability
of prion replication, oBM-MSCs cultures were seeded at 5000 cells/cm2 for proliferation
conditions and at 1500 cells/cm2 for neurogenic conditions. In both cases, three groups
were established: positive, negative and control cultures. Positive cultures were infected
with inocula from a scrapie-infected sheep, negative cultures with inocula from a healthy
sheep and control cultures were kept in standard conditions. After adhesion for 24 h, basal
media was substituted by inocula diluted 1:10 in DMEM media (10% FBS, 1% L-glutamine
and 1% streptomycin/penicillin) for the oBM-MSC cultures and in HyClone media for the
oBM-MSC cultures in neurogenic differentiation. Cells were maintained in this medium for
48 h to analyze the proliferation potential and cell viability and for 72 h for the MTT/ELISA
assays. Afterwards, the medium was changed twice a week.
2.5. Proliferation Potential and Cell Viability
To determine the effect of prion infection on oBM-MSC proliferation potential, cul-
tures from three different donors (biological replicates) were seeded in 6-well plates at
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5000 cells/cm2, inoculated with scrapie and control inocula and maintained until passage
3 post-infection; every passage was performed at around 80% confluence. Adherent cells
were counted every passage and the cell doubling number (CD) and cell doubling time
(DT), used to determine the time it takes for a population of cells to double in size, were
calculated as previously described [21,24]. The results were evaluated using the paired
Student’s t-test.
To assess early prion toxicity, cell viability was also evaluated using MTT in oBM-MSC
from 8 donors at 3, 7 and 10 days post-inoculation (dpi), seeding 4 technical replicates
for each culture. oBM-MSC cultures were seeded in 96-well plates at 5000 cells/cm2 in
growth conditions and at 1500 cells/cm2 in neurogenic differentiation conditions. Briefly,
the MTT assay was performed by adding 25 µL of MTT solution (2 mg/mL) per well.
Then, the plates were incubated at 37 ◦C for 4 h. Afterwards, the content of each well was
removed and was substituted with 150 µL of HCl solution (HCl 40 mM in isopropanol)
per well. Plates were then incubated for 1 h at room temperature protected from light.
The absorbance was measured at 570 nm in an Infinite F200 microplate reader (Tecan
Ibérica Instrumentación, Barcelona, Spain). A calibration curve was prepared with different
amounts of cells. Since oBM-MSCs in growth conditions are seeded in a higher density than
the ones in neurogenic differentiation conditions, two calibration curves were prepared:
a more concentrated one to compare oBM-MSCs in growth conditions (Figure S1a) and
a more diluted one to compare cultures in neurogenic conditions (Figure S1b). In both
cases, the calibration curve enabled us to establish the relationship between absorbance
and the amount of cultured cells. The toxicity of the prion was studied in three conditions
(inoculated with scrapie-positive brain homogenates, negative brain inoculum and non-
inoculated controls) and at three different stages (3, 7 and 10 dpi). As cells were kept in
contact with the inoculum for 72 h, the stage 3 dpi corresponds to the moment just after
inoculum removal. The moment of the infection with the inocula was considered as day 0.
The normality of the results was evaluated with Shapiro–Wilk and D’Agostino–Pearson
tests. Differences in cell viability and proliferation were evaluated with Student’s t-test.
Statistical significance was defined as p < 0.05.
2.6. PrPSc Detection
Cells from the three biological replicates analyzed in the proliferation assay were
used to evaluate if PrPSc was increased or maintained along the passages in MSC cultures
infected with scrapie and maintained under grown conditions. Approximately 106 cells of
passages 1, 2 and 3 post-infection were frozen at −80 ◦C for further PrPSc determination by
Western blotting. Pellets of frozen cells were homogenized in 100 µL of PBS. Afterwards,
samples were analyzed using the BSE Scrapie Discriminatory Kit (Bio-Rad Laboratories,
Hercules, CA, USA) and treated following the manufacturer’s recommendations. Elec-
trophoresis was developed in 12% SDS-PAGE gels. Protein was then transferred to a
0.20-µm nitrocellulose membrane (Bio-Rad). CDP-Star substrate (ThermoFisher Scientific,
Westbrook, ME, USA) was used to determine chemiluminescence in a Versa-Doc Imaging
System (Bio-Rad Laboratories). Chemiluminescence signals were evaluated using ImageJ
1.4.3.67 (Psion Image), as described previously [27].
Neurogenic differentiation of MSCs requires seeding cells at low density and differen-
tiated cells cannot be maintained along passages. To test the ability of these cells to replicate
PrPSc, we quantified the amount of the pathogenic protein soon after prion infection at
three different stages (3 dpi, which corresponds to inoculum removal, 7 and 10 dpi) in
oBM-MSCs in growth and neurogenic differentiation conditions. We used a more sensitive
test, the ELISA kit EEB-Scrapie HerdCheck kit (IDEXX), following the manufacturer’s
recommendations. oBM-MSCs cultures from 5 donors were seeded in 6-well plates and
the retrieval of the cells was performed by means of trypsinization and subsequent cen-
trifugation. To quantify the PrPSc detection range of the ELISA kit, a calibration curve was
performed using different concentrations of scrapie inocula (Figure S2). PrPSc was detected
in all inoculum concentrations, showing that this kit is suitable to detect PrPSc in oBM-MSC
Animals 2021, 11, 1137 6 of 13
cultures, as the amount of inocula used in oBM-MSC infection was higher than the most
diluted concentration of the calibration curve. The inoculum used in the calibration curve
was the same used to infect oBM-MSCs in growth and neurogenic conditions. For infection,
a volume of 100 µL of scrapie inoculum per well was employed, which would correspond
to >3 units of absorbance.
3. Results
3.1. Proliferation Potential of Infected oBM-MSC
The effect of scrapie infection on the proliferation capacity was analyzed in oBM-MSCs,
calculating the CD and DT. Significant differences between cultures infected with scrapie
and control inocula were found for both CD and DT at the first passage post-infection. CD
was higher and DT was lower in the cultures treated with control inocula compared to
those inoculated with scrapie brain cells (Table 2).
Table 2. Cell doubling number (CD) and cell doubling time (DT) of oBM-MSCs from 3 donors
through passages 1 to 3 post-inoculation with 1% brain homogenates obtained from healthy and







3.150 ± 0.286 * 2.949 ± 0.219 *




3.22 ± 0.651 2.870 ± 0.531




1.93 ± 0.390 1.807 ± 0.027




2.871 ± 0.711 * 2.634 ± 0.597 *
1.942 ± 0.469 2.097 ± 0.469
Significant differences were calculated using Student’s t-test (* p < 0.05, ** p < 0.01).
3.2. Cell Viability of Infected Cultures
The effect of prion infection on cell viability was studied in three conditions (scrapie
positive inoculum, healthy/negative inoculum and control without inoculum) and at three
different stages (3, 7 and 10 dpi) in oBM-MSCs in growth conditions and in
neurogenic differentiation.
Proliferation was evidenced in oBM-MSC cultures maintained in growth medium
under the three conditions. Inoculated cultures displayed higher number of cells than
controls at the three stages (3, 7 and 10 dpi). Proliferation was significantly lower in scrapie
infected cells than in cultures treated with negative inocula at 3 dpi but, in subsequent
stages (7 and 10 dpi), the positive cultures displayed significantly more cells than the
negative cultures (Figure 2a).
In neurogenic differentiation conditions, the number of cells also increased over time
in the three conditions, whereas inoculated cultures showed a higher growth than controls.
Comparing between the inoculated cultures, the number of cells was significantly higher
in cultures that were in contact with negative inoculum than the ones infected with scrapie,
and this difference was statistically significant at 10 dpi (Figure 2b).
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Figure 2. Cell viability study by MTT in infected oBM-MSC cultures in growth conditions (a) and
neurogenic differentiation (b) 3, 7 and 10 days post-inoculation (dpi). oBM-MSCs were from
8 different donors and 4 technical replicates per culture were seeded. Significant differences were
calculated using the Student t-test (* p < 0.05, ** p < 0.01, *** p < 0.001).
3.3. PrPSc Detection in Infected oBM-MSCs, Analyzed by Western Blotting
After inoculation of oBM-MSCs in growth conditions, surviving cells retained their
ability to proliferate and were expanded until passage 3 post-infection. Western blotting
analysis revealed the presence of PrPSc in the cultures during these three passages although
the intensity of bands decreased with the number of passages (Figures 3 and S3) and was
lost in further subcultures.
Figure 3. Determination of PrPSc by Western blotting in oBM-MSCs (BM1, BM2, BM3) in-
fected with scrapie inocula at passages 1 to 3 (P1, P2, P3). MWSC = molecular weight marker;
C (+) = positive control.
3.4. Prion Detection by ELISA in oBM-MSC and Neuron-Like Cultures Infected with Scrapie
To test the ability of MSC-derived neuron-like cells to replicate prions, the presence of
PrPSc was studied by means of ELISA immediately after infection at three different stages
(3, 7 and 10 dpi) in oBM-MSCs infected with positive inocula in growth and neurogenic
differentiation conditions.
In oBM-MSCs maintained under growth conditions, a decrease in ELISA absorbance
was observed, which could be associated with a loss of the PrPSc signal. Significant
differences were found between 3 dpi and 7 dpi (p < 0.05) and 3 dpi and 10 dpi (p < 0.01)
(Figure 4a).
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Figure 4. PrPSc detection via ELISA in infected oBM-MSC cultures from 5 donors in growth (a,b) and
neurogenic differentiation (c,d) conditions 3, 7 and 10 days post-inoculation (dpi). Significant
differences were calculated using Student’s t-test (* p < 0.05, ** p < 0.01).
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In contrast, the majority (four out of five) of neuron-like differentiated cultures showed
an increase in absorbance over time, which could be associated with a progressive increase
in the PrPSc signal. Even though most of the cultures had an increasing signal pattern, as
one of them (BMO4) displayed decreased absorbance over time, no significant differences
were found between any of the three stages (Figure 4b).
Although we used the same inoculum in all cultures, the initial amount of PrPSc was
different in each culture at 3 dpi, suggesting a heterogeneity in the ability to retain prions.
Higher cellular density under growth conditions would explain the higher absorbance
observed in this condition, compared to neurogenic conditions.
4. Discussion
Prion diseases are fatal neurodegenerative disorders affecting humans and animals.
Over the years, a substantial effort has been made to develop in vitro models for the
study of these pathologies. Most of the cellular models are based on the culturing of
murine cell lines [8] and require a previous adaptation of the strain to mice, due to the
well-known phenomenon of the species barrier. Therefore, in vitro models with a natural
host background would be very useful tools for research into many prion topics, e.g.,
prion replication, toxicity, genetic susceptibility, differences in strain susceptibility, early
mechanisms of infection and new treatment testing.
MSCs can be easily collected from several accessible adult tissues like bone marrow
or peripheral blood [8,28] and they show the ability to transdifferentiate into neuronal
elements in vitro [10,29]. Several works have described the ability of murine stromal cells
to propagate prion infectivity [12,17,30,31] and expanded MSCs obtained from sporadic
Creutzfeldt-Jakob disease CJD patients have been shown to be positive for PrPSc [12]. The
infectivity of MSCs obtained from sick individuals does not seem to be a pan-species
characteristic, as oBM-MSCs from scrapie infected sheep did not show PrPSc [18]. Al-
though MSCs derived from human, cattle and sheep express PrPC [12,18] to the best of
our knowledge, the potential of MSCs derived from these naturally susceptible species
to propagate prion infection in vitro has never been investigated. In the present work,
we infected ovine bone marrow-derived MSCs and their neuron-like derivatives with
scrapie-infected sheep isolates to study the response of these cells to prion infection during
a certain period of time.
MSCs can migrate to prion-affected neurological tissues as a response to secreting
trophic factors that activate endogenous restorative reactions in the injured brain [32–34].
In our study, cell viability was higher in both oBM-MSCs and neural-differentiated cultures
after inoculation compared with non-inoculated control cultures in the three monitored
stages (3, 7 and 10 dpi), which suggests that brain inocula, independently of their origin,
may contain factors that stimulate oBM-MSC proliferation.
Murine stromal cells are able to propagate prions for many passages [17,30]. On
the contrary, oBM-MSCs do not seem to be permissive to PrPSc infection. The loss of
PrPSc signal over time detected by ELISA in oBM-MSC cultures soon after infection with
positive inocula suggests that these cells, if infected, are unable to replicate the prions,
unlike what happens in mice. Similarly, Western blotting revealed the presence of PrPSc in
scrapie-infected oBM-MSC cultures three passages after inoculation, but the presence of the
pathologic protein seemed also to be weakened between passages 2 and 3, suggesting that
PrPSc may be taken up by oBM-MSCs without leading to a successful prion infection. In
some works, murine BM-MSCs infected with prions in vitro showed few or no PrPSc pro-
duction during the first 10 or even 50 passages [12,31] and stable and detectable (by Western
blotting) production of PrPSc afterwards. We could not explore this possibility because,
contrary to murine cells, MSCs obtained from humans or unconventional model organisms
including sheep are able to be maintained in culture for far fewer passages [35,36].
Moreover, after inoculation with scrapie, oBM-MSC cultures displayed a high pro-
liferation rate, with an average doubling time during the three passages that was lower
than the DT described previously for BM-MSC cultures derived from scrapie and healthy
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sheep [18]. Cell division modulates prion accumulation in cultured cells [37] and direct
proximity between donor and recipient cells increases the infection in other cell culture
models [38]. The high proliferation rate observed in oBM-MSCs could help to avoid the
transmission of PrPSc from infected cells to non-infected ones because the cells are not in
contact for a long enough time. Therefore, only the cells infected during the inoculation
process and their daughters would show infection and this would be diluted in successive
passages. Changes in culture conditions focused on slowing down the proliferation rate or
increasing their contact in spheroid cultures could facilitate the propagation.
On the other hand, we cannot discard the possibility that infection with scrapie-
infected brain cells could be toxic for the oBM-MSC cultures. Even though no toxicity was
observed in murine MSCs infected with the CJD agent [12], we have to take into account
that our cells come from a naturally susceptible host. In our study, CD was significantly
higher in cells infected with healthy brain extracts and, accordingly, DT was higher in cells
infected with scrapie inocula. Therefore, those cells exposed to scrapie prions showed lower
proliferation potential, similar to the findings observed in MSCs obtained from scrapie
sheep [18]. This could be a consequence of the loss of infected cells due to prion toxicity. In
the MTT assay, the effect of prion infection on cell viability was evaluated during the first
passage after prion infection. Toxicity seems to be an early effect of prion infection, as 3 days
after inoculation, viability was lower in scrapie cultures than in healthy infected cultures.
In contrast with the first assay, at the end of this passage (10 dpi), the number of cells in
scrapie-infected cultures was higher than that in the cultures inoculated with control brain
cells. This could be a consequence of differences in the inocula, as brain tissues used in the
different experiments were different and could have contained different amounts of PrPSc
and therefore exhibited different degrees of toxicity. Nevertheless, throughout all passages,
CD and DT differences were lower and, similarly, the number of cells in scrapie-infected
cultures increased after early toxicity. In both cases, this increase in proliferation and
viability was accompanied by the loss of PrPSc detection, which might indicate a recovery
of the cell culture conditions after the elimination of PrPSc infected cells, increasing the
proportion of non-infected cells, which display higher proliferation potential.
Regarding the differentiation of oBM-MSC cultures into neuron-like cells, although
certain toxicity was also observed 3 days after prion infection, four out of the five cultures
analyzed seemed to be infected and possibly displayed the ability to replicate the patholog-
ical prion protein. Although we did not obtain statistical support for this observation, the
ELISA assay showed that these cells maintained the PrPSc signal and this signal increased
progressively over time. Similarly, astrocytes derived from human induced pluripotent
stem cells are capable of replicating prions from brain samples of CJD patients, generating
prion infectivity in vitro [20]. Taking this into account and knowing that cells from the
central nervous system are the target of the pathological prion protein, oBM-MSC-derived
neuron-like cells may have a greater ability to capture and replicate PrPSc than oBM-MSCs
in growth conditions. The lack of statistical significance in our results was due to the
existence of variability in prion replication, as one culture (BMO4) failed to replicate prions.
This culture displayed a PRNP genotype identical to other three cultures (ARQ/ARQ),
suggesting that, in addition to the PRNP genotype, other factors influence prion replication.
Despite all the cultures being infected with the same amount of inoculum, BMO4 was the
one that showed the highest absorbance for PrPSc under both growth and differentiation
conditions. Differences in the ability to access prions could explain differences in toxicity
and prion replication.
The observed differences in undifferentiated and differentiated oBM-MSCs suggest
that the latter possess a competence for infection that it is not present at the MSC stage,
even though they share a genetic background for each given animal. This system, using
oBM-MSC-neuron-like derivates, could serve for the investigation (in an isogenic context)
of the molecular trigger that sustains scrapie infection in vitro, specifically in the neural
lineage. In addition, differences between cultures harboring the same PRNP genotype
could help in the identification of other factors related to prion susceptibility.
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5. Conclusions
This work describes for the first time the infection with scrapie agents of bone marrow-
derived MSCs obtained from sheep, which is a natural host of prion diseases. Culturing
ovine MSCs with CNS extracts in growth and neurogenic conditions induced cell pro-
liferation, although some toxicity was observed in scrapie-infected cultures. Inoculated
oBM-MSCs in growth conditions were not permissive to prion infection, whereas most
cultures under neurogenic differentiation conditions seemed to retain and replicate the
pathological prion protein. oBM-MSC-derived neuron-like cells could be a good can-
didate for developing in vitro studies in species for which iPSC reprogramming is not
standardized, like sheep. Further studies focusing on elucidating the molecular mecha-
nisms implicated in retaining prion infectivity and inducing prion toxicity in mesenchymal
stem cells and MSC-derived neuron-like cells are warranted.
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